epiClinicalA fictional CRO

epiClinical is fictional. It is a portfolio demonstration by Adam Daniels. Its studies, sponsors, sites and enrolment figures are synthetic. The evidence behind its assumptions is real, and every number says how far it can be trusted.

EPI-405, Phase III. Recruiting

A rare inherited neuromuscular disorder (genetically confirmed)

TSR-405 against placebo in an inherited neuromuscular disorder. Sponsor: Tailspin Rare Diseases (fictional), Rare disease.

Twenty questions about the protocol, each tied to the research, and what every answer does to recruitment. The answers start as this study's template; change any of them to see what moves.

Tailspin Rare Diseases (fictional), Phase III, Rare disease. Protocol final September 2024. The answers start as this study's protocol; change any of them to see what moves.

All answers match the protocol.

Population and eligibility

How many non-essential exclusions does the protocol carry?

Organ-function limits, brain metastases, prior or concurrent cancers, performance status, and similar criteria that are not needed for safety.

  • Rate ×1: Protocol and population: Standard
Which line of therapy does the study enrol?
  • No effect on the forecast
Is the population an orphan subgroup?

Not used with the rare-disease therapeutic area, which already carries the effect.

  • No effect on the forecast
Does entry require a biomarker, and how common is it?
  • Screening Most screened patients will fail; plan pre-screening and central testing

Risks: PD-12PM-05

Does the protocol exclude common comorbidities?
  • No effect on the forecast
Is there an upper age limit?
  • Risk flag Older adults are under-enrolled: 25% of trial entrants against 63% of cancer patients

Risks: PB-10

Design

What does the control arm receive?
  • Rate ×0.75: Placebo or no added treatment (D15)

Risks: PD-05PD-17

Is the study blinded?
  • Rate ×0.8: Blinded (D15)

Risks: PD-06EB-03

What is the randomisation ratio?
  • Risk flag Often used to aid recruitment, but no recruitment benefit has been documented

Risks: PD-07

Is there a run-in or a washout longer than four weeks?
  • No effect on the forecast

Patient burden

How heavy is the visit and procedure schedule?

Compare with similar studies in the same area: number of visits, invasive procedures, questionnaires, overnight stays.

  • Rate ×0.8: Heavier than typical (D17)
  • Retention Higher burden raises drop-out

Risks: PD-03S-24EB-17

Are any visits done remotely or at home?
  • Risk flag Helps distant patients; no recruitment effect is established

Risks: PD-20

Did patients help design the protocol?
  • Rate ×1.1: Yes (D17)

Operations

How settled is the protocol?
  • No effect on the forecast
How many vendors and systems will sites use?
  • No effect on the forecast
What kind of sites will the study mostly use?
  • No effect on the forecast

Risks: S-06PM-02

Have most sites worked with the sponsor before?
  • No effect on the forecast

Risks: S-04

Environment

How many competing trials recruit the same patients?
  • Rate ×1.1: Competing trials: None
Could the standard of care change during the study?
  • No effect on the forecast
Does the study depend on a comparator or backbone drug that has been in short supply?
  • No effect on the forecast

Build a site

A site's rate is built one factor at a time. The questionnaire sets each row, or pick an option to try a different kind of site in every country.

Each country's usual mix of site types, shifted by the site mix answer
Expected mix for mostly repeat sites
Standard ×1
None ×1.1

Poland recruits fastest per site, at 0.092 a month

Patients randomised per site per month after each factor, by countryDots: filled is evidence-anchored, half-filled takes its direction from evidence, hollow is an assumption, hatched combines several; United States highlighted

Source: epiClinical evidence library; each factor's basis and source are in the rows beside the chart.

Shaded: Industry Phase III median, 0.4. Median 0.4 patients per site per month (interquartile range 0.2 to 0.6) in completed industry Phase III trials, 2016 to 2019 (PLOS ONE 2022; D01).

Shaded: UK public trials median, 0.92 to 0.95. Median 0.92 to 0.95 patients per centre per month in UK publicly funded trials (Walters 2017; Jacques 2022; D01).

Show data
Patients randomised per site per month after each factor, by country
FactorUnited StatesUnited KingdomSpainPolandTurkeyIndia
Therapeutic area0.1000.1000.1000.1000.1000.100
Country0.0750.0850.1000.1400.1000.110
Site type0.0740.0840.0990.1430.0980.106
Track record0.0730.0820.0970.1400.0960.104
Protocol and population0.0730.0820.0970.1400.0960.104
Patient acceptability0.0440.0490.0580.0840.0580.063
Competing trials0.0480.0540.0640.0920.0630.069

What this design does to the sites needed

To finish by March 2027 with 85% confidence, this design needs about 67 sites, the same as the protocol as written.

CountryPer site per month, protocol as writtenWith this designChangeSites needed, protocolWith this design
United States0.0480.048–00
United Kingdom0.0540.054–00
Spain0.0640.064–00
Poland0.0920.092–4141
Turkey0.0630.063–1111
India0.0690.069–1515

Forecast this design

Risks these answers switch on

Open a risk to see its effect, what helped, what did not and the sources. Grade A is the strongest evidence and D the weakest.

Protocol and design

PD-12Biomarker-selected population with low marker prevalence Grade B
Effect
Negative; 37.6% actionable and 17.8% assigned in NCI-MATCH; 39 to 70% amyloid-negative at screening; MASH screen failure 56%.
What helped
Central screening at scale (1,117 sites); EHR and registry pre-screening.
What did not
not found
Sources
Flaherty 2020; Sevigny 2016; Sperling 2020; Souza 2025
PM-05Screen failure is high and varies widely by therapeutic area Grade A
Effect
Cuts randomised patients per screened: 36.3% overall and rising, CNS 57%, rare disease 81% ineligible, inflammatory bowel disease 43% to 53%, heart failure outcome trials 42% to 48%, COPD 37% to 42%, oncology 34% to 51%.
What helped
not found
What did not
Protocol planning assumptions of 10% for asthma and 20% for COPD were exceeded two to four times over in three COPD Phase III programmes.
Sources
Tufts CSDD 2019; Tufts CSDD 2012; IBD trials analysis 2025; UCSD 2022; Tata 2023; DAPA-HF and EMPEROR-Reduced dispositions2; COPD letter
PB-10Older adults under-enrolled Grade A
Effect
People aged 65 and over were 25% of trial entrants against 63% of cancer patients; trial median age 6.49 years below the population; 70 and over are 24% of FDA-registered trial participants against 42% of the cancer population.
What helped
Coverage policy raised 65 and over accrual (Unger 2006); broader eligibility and fewer performance-status cut-offs narrow the gap (Ludmir 2019).
What did not
Physician geriatric education, cluster RCT across 126 institutions, no effect (Kimmick 2005).
Sources
Hutchins 1999; Ludmir 2019; Sedrak 2021; FDA Snapshots 2024
PD-05Placebo or no-added-treatment control arm Grade B
Effect
Negative; willingness 30% against 39%; acceptance 60.5% against 80.6%.
What helped
All-active arms; add-on designs; equipoise-focused recruiter training through the QRI.
What did not
not found
Sources
Welton 1999; Jenkins 2000; Mills 2006; Uzzan 2023
PD-17Active comparator (against placebo) in registry data Grade B
Effect
Negative association only; poor accrual 23% against 16%.
What helped
not found
What did not
not found
Sources
Carlisle 2015
PD-06Blinded placebo-controlled against open design Grade A
Effect
Negative for blinding; an open design adds 10 percentage points (95% CI 7 to 13), high certainty.
What helped
Open or PROBE design where scientifically acceptable.
What did not
User-tested information leaflets added 1 point, no effect.
Sources
Treweek 2018
EB-03Blinded placebo-controlled design instead of open-label Grade A
Effect
Open design recruits 10 percentage points more of eligible patients (95% CI 7 to 13); at trial level active-comparator trials failed accrual more often than placebo trials (23% against 16%), and per-centre rates did not differ significantly.
What helped
Open-label or pragmatic design where scientifically acceptable (high certainty).
What did not
not found
Sources
Treweek 2018; Carlisle 2015; Walters 2017; Jacques 2022
PD-07Unequal randomisation ratio used to aid recruitment Grade C
Effect
Unclear; 57% of trials give no rationale and no recruitment benefit is documented.
What helped
not found
What did not
The claimed recruitment benefit is unproven.
Sources
Dumville 2006
PD-03Procedural and visit burden (visits, blood draws, questionnaires) Grade B
Effect
Negative; burden score predicts screen failure, trial duration, and amendments (p < 0.01); oncology plans 29 visits against 16.
What helped
Score burden at design; prune non-core procedures, which are 22 to 25% of all procedures.
What did not
Sites rate decentralised trials as more burdensome for patient-facing procedures.
Sources
Smith 2021; Dirks 2025; Getz 2023
S-24Protocol complexity and site burden Grade B
Effect
Negative: procedures up 40.6%, sites per protocol up 60.1%, and enrolment duration up 36.9% (2010 to 2020); 70% of site staff say trials are much harder; about one-third of data collected is non-core.
What helped
Remove non-core data and procedures. Take site input on design.
What did not
not found
Sources
Clinical Trial Vanguard 2024; WCG 2024; Tufts CSDD 2022; PharmaVoice 2025
EB-17Follow-up burden and duration Grade C
Effect
Negative; trials with final follow-up beyond 18 months recruit at 0.71 per centre per month against 1.29 for follow-up within a month (p=0.054); time commitment is a key deterrent in the qualitative synthesis.
What helped
Reducing visit burden (CTTI, not quantified).
What did not
not found
Sources
Jacques 2022; Houghton 2020
PD-20Decentralised elements Grade C
Effect
Unclear; modelled value only; sites split on whether they add or remove burden.
What helped
Hybrid elements for follow-up visits.
What did not
A fully remote trial under-recruited despite a very large outreach funnel.
Sources
FDA 2024; DiMasi 2023; Nassif 2023; Florez 2024

Site

S-06Site type: activation speed Grade A
Effect
Negative for academic and hospital sites: median 8.1 months versus 4.4 months for independent sites; 9% versus 54% start within 60 days; 21%, 34%, and 80% within 60 days for AMCs, hospital systems, and investigative sites.
What helped
Standardised start-up workflow with a site navigator (133 versus 277 days). Master contracts. UK National Contract Value Review (305 to 194 days).
What did not
Sequential review layers. Pre-activation amendments, which add 4 to 6 weeks each.
Sources
Smith (WCG) 2024; Advarra 2020; WCG 2025; Dilts and Sandler 2006
PM-02Academic and hospital sites, and sites new to the sponsor, take longer to activate Grade B
Effect
Delays activation by months: 8.1 to 9.4 months for academic medical centres against 4.4 to 4.8 for independent sites, 12.9 against 7.9 months from pre-study visit to first patient, and 35.6 weeks for new sites against 25.7 for repeat sites.
What helped
not found
What did not
not found
Sources
WCG Data Intelligence 2023 to 2025; Tufts CSDD 2012; Tufts CSDD 2018
S-04Past performance as a predictor Grade B
Effect
Positive but modest: Spearman 0.13 to 0.16 for historical rate alone and 0.37 to 0.46 with patient-volume data; well-performing sites have a 70% higher chance of out-performing; trial-manager predictions reach 82% sensitivity but 32% specificity.
What helped
Combine historical rate with real-world patient volume, referral flow, and research experience. Guided prediction forms with red flags.
What did not
Historical performance alone. Unguided judgement after the initiation visit.
Sources
Getz 2011; Hulstaert 2024; Bruhn 2019; Yang 2018; Ninh 2026